Royalty Pharma PLC 10-Q quarterly reports

Royalty Pharma plc reported a significant increase in income from financial royalty assets and other revenues for the second quarter and first six months of 2026.

Royalty Pharma plc reported a significant increase in total income and other revenues for the first quarter of 2026, driven by strong performance across its financial royalty assets.

Royalty Pharma reports a decline in GAAP net income and EPS for Q3 and the first nine months of 2025, primarily due to accounting changes from its internalization and increased R&D funding, while Portfolio Receipts show strong growth.

Royalty Pharma plc reported a significant increase in net income and earnings per share for the first half of 2025, driven by a positive swing in non-cash provision income and robust portfolio receipts, alongside substantial share repurchases.

Royalty Pharma plc reports relatively flat income from financial royalty assets and announces progress on its internalization plans in its Q1 2025 report.

Royalty Pharma's Q3 2024 results show a significant increase in net income, reaching $806 million, driven by strong royalty income and strategic financial activities.

Royalty Pharma's second-quarter results show a slight increase in income from financial royalty assets but a decrease in other royalty income and revenues, alongside significant changes in operating expenses.

Royalty Pharma's first quarter saw a decrease in income from financial royalty assets, offset by gains in other areas, resulting in a net loss for the quarter.